A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms PARAGON-HF
- Sponsors Novartis
- 09 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Jun 2016 Planned primary completion date changed from 1 May 2019 to 1 Mar 2019.
- 12 Jun 2016 Planned End Date changed from 1 May 2019 to 1 Mar 2019.